XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Description of Business
6 Months Ended
Jun. 30, 2020
Organization and Basis of Presentation [Abstract]  
ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

INmune Bio, Inc. (the "Company" or "INmune Bio") was organized in the State of Nevada on September 25, 2015, and is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. INmune Bio's focus is on the innate immune system that include natural killer cells ("NK cells"), hepatic stellate cells of the liver (HSC cells), myeloid derived suppressor cells ("MDSC cells"), microglial cells and dendritic cells ("DC cells"), to offer unique therapeutic opportunities. INmune Bio plans to develop their four existing drug platforms: INKmune ("INKmune") which primes NK cells, INB03 ("INB03") which down regulates MDSC cells, LivNate, which targets soluble TNF – a key cytokine driving pathologic chronic inflammation, and XPro1595 that targets microglial cell activation in the brain – a cause of neuroinflammation.  INmune Bio is also initiating a clinical program to determine if the Company's TNF Inhibitor ("DN-TNF") platform may prevent complications of cytokine storm from COVID-19.

 

The Company has been actively monitoring the novel coronavirus ("COVID-19") situation and its impact globally. The Company has continued to operate as it had prior to the COVID-19 pandemic with minimal change, other than for enhanced safety measures intended to prevent the spread of the virus.